Tauri 5-in-1 iPhone 16 Plus Case. The Tauri 5-in-1 iPhone 16 Plus Case offers military-grade protection with raised edges to ...

Unleash your creativity with these fun DIY projects for making adorable purses, credit card holders, and phone cases. Using ...

Here’s a look at all the camera gear, gadgets, and accessories I've packed for CES 2025 and why it’s my ultimate survival kit ...

These are my most-used iPhone accessories of 2024. From a MagSafe-compatible stand to a case with 36 Action buttons, there's ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

In a phase 3 clinical trial investigating the usefulness of its anti-obesity drug candidate CagriSema, after being injected weekly for 68 weeks, patients lost 22.7% of their weight on average.

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

On Monday, BMO Capital Markets adjusted its stance on Novo Nordisk (NYSE:NVO) shares following the release of Phase 3 clinical trial results for the company's diabetes treatment, CagriSema. The price ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the release of ...

On Monday, BMO Capital Markets adjusted its stance on Novo Nordisk (NYSE:NVO) shares following the release of Phase 3 clinical trial results for the company's diabetes treatment, CagriSema.

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated comp ...